ASCO 2017 | Developing alternative treatment options for advanced melanoma

Dirk Schadendorf, MD from the West German Cancer Centre, University Hospital Essen, Germany discusses an alternative treatment option for patients with advanced melanoma (MEL), who have failed therapy with ipilimumab. A safety study was conducted on a large number of patients with all kinds of disease conditions such brain metastasis, which are usually excluded from the study. This step was taken to gain an understanding and produce data that reflect the reality of patients with advanced melanoma. Interesting observations were made from this data. Recorded at the American Society of Oncology (ASCO) 2017 Annual Meeting held in Chicago, IL.